| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 09/07/2001 | WO2001064665A1 Chroman derivatives as estrogenic compounds |
| 09/07/2001 | WO2001064663A2 Biologically active analogs of discodermolide |
| 09/07/2001 | WO2001064660A1 Novel quinoline ligands and metal complexes for diagnosis and therapy |
| 09/07/2001 | WO2001064656A1 2,4,di(hetero-)arylamino(-oxy)-5-substituted pyrimidines as antineoplastic agents |
| 09/07/2001 | WO2001064655A1 2, 4-di(hetero-)arylamino (-oxy)-5-substituted pyrimidines as antineoplastic agents |
| 09/07/2001 | WO2001064654A1 Pyrimidine compounds |
| 09/07/2001 | WO2001064653A1 Pyrimidine compounds |
| 09/07/2001 | WO2001064650A2 Synthesis of epothilones, intermediates thereto and analogues thereof |
| 09/07/2001 | WO2001064639A2 Pde iv inhibiting amides, compositions and pharmaceutical use |
| 09/07/2001 | WO2001064635A1 Ningalin b analogs employable for reversing multidrug resistance |
| 09/07/2001 | WO2001064634A1 Pharmaceutical compositions containing azetidine derivatives, novel azetidine derivatives and preparation thereof |
| 09/07/2001 | WO2001064633A1 Pharmaceutical compositions containing 3-amino-azetidine derivatives, novel derivatives and preparation thereof |
| 09/07/2001 | WO2001064632A1 Azetidine derivatives, preparation thereof and pharmaceutical compositions containing same |
| 09/07/2001 | WO2001064255A1 Method for detecting and killing epithelial cancer cells |
| 09/07/2001 | WO2001064252A2 Farnesyl protein transferase inhibitor combinations with further anti-cancer agents |
| 09/07/2001 | WO2001064251A2 Combination chemotherapy |
| 09/07/2001 | WO2001064249A1 Tissue decomposition inhibitor |
| 09/07/2001 | WO2001064247A2 Method of treating cancer with anti-neurotrophin agents |
| 09/07/2001 | WO2001064246A2 Farnesyl protein transferase inhibitor combinations with an her2 antibody |
| 09/07/2001 | WO2001064236A2 METHODS FOR TREATING FSH RELATED CONDITIONS WITH GnRH ANTAGONISTS |
| 09/07/2001 | WO2001064235A1 Methods for treating, screening for, and detecting cancers expressing vascular endothelial growth factor d |
| 09/07/2001 | WO2001064226A2 Farnesyl protein transferase inhibitor combinations with platinum compounds |
| 09/07/2001 | WO2001064218A2 Farnesyl protein transferase inhibitor combinations |
| 09/07/2001 | WO2001064217A2 Combinations of a farnesyl protein transferase inhibitor with nitrogen mustard or nitrosourea alkylating agents |
| 09/07/2001 | WO2001064214A2 Compositions and methods for the treatment of inflammatory diseases using topoisomerase inhibitors |
| 09/07/2001 | WO2001064208A1 Il-8 receptor antagonists |
| 09/07/2001 | WO2001064199A2 Farnesyl protein transferase inhibitor combinations with taxane compounds |
| 09/07/2001 | WO2001064198A2 Farnesyl protein transferase inhibitor combinations with anti-tumor podophyllotoxin derivatives |
| 09/07/2001 | WO2001064197A2 Farnesyl protein transferase inhibitor combinations with anti-tumor anthracycline derivatives |
| 09/07/2001 | WO2001064196A2 Farnesyl protein transferase inhibitor combinations with vinca alkaloids |
| 09/07/2001 | WO2001064195A2 Farnesyl protein transferase inhibitor combinations with anti-tumor nucleoside derivatives |
| 09/07/2001 | WO2001064194A2 Farnesyl protein transferase inhibitor combinations with camptothecin compounds |
| 09/07/2001 | WO2001064193A2 Exemestane for first-line treatment of breast cancer |
| 09/07/2001 | WO2001064165A2 Il-8 receptor antagonists |
| 09/07/2001 | WO2001064164A2 Nanocapsule encapsulation system and method |
| 09/07/2001 | WO2001064110A1 Method for detecting and killing epithelial cancer cells |
| 09/07/2001 | WO2001064057A1 Novel pharmaceutical or dietetic mushroom-based compositions |
| 09/07/2001 | WO2001019823A3 Substituted pyridino pentaazamacrocyle complexes having superoxide dismutase activity |
| 09/07/2001 | WO2001016135A3 Reverse-turn mimetics and methods relating thereto |
| 09/07/2001 | WO2001014395A3 Novel glycoconjugates, glycoamino, acids, intermediates thereto, and uses thereof |
| 09/07/2001 | WO2001014379A3 A novel crystalline form of disodium n-[4-[2-(2-amino-4,7-dihydro-4-oxo-3h-pyrrolo[2,3-d]-pyrimidin-5-yl)ethyl]benzoyl]-l-glutamic acid salt and processes therefor |
| 09/07/2001 | WO2001013901A3 A pharmaceutical delivery system for vitamin c and vitamin e and use of a combination of vitamin c and e for preventing or treating conditions involving oxidative stress |
| 09/07/2001 | WO2001010841A3 Fluorene derivatives as integrin inhibitors |
| 09/07/2001 | WO2001010423A3 Use of 5-ht3 receptor antagonists for the treatment of inflammations of the respiratory tract |
| 09/07/2001 | WO2001010383A3 Caspase inhibitors and uses thereof |
| 09/07/2001 | WO2001005823A3 Tryptase inhibitor |
| 09/07/2001 | WO2000076528A3 Pharmaceutical preparation containing proteins |
| 09/07/2001 | WO2000075107A3 Bradykinin receptor antagonists |
| 09/07/2001 | WO2000071571A3 Fap-activated anti-tumor compounds |
| 09/07/2001 | WO2000062765A3 ESTROGEN RECEPTOR-β LIGANDS |
| 09/07/2001 | WO2000047603A9 16-hydroxyestratrienes as selective estrogens |
| 09/07/2001 | WO2000002912A3 Disintegrin homologs |
| 09/07/2001 | CA2401800A1 Synthesis of epothilones, intermediates thereto and analogues thereof |
| 09/07/2001 | CA2401741A1 Melanoma differentiation associated gene - 5 and promoter and uses thereof |
| 09/07/2001 | CA2401697A1 Pyrazole ether derivatives as anti-inflammatory/analgesic agents |
| 09/07/2001 | CA2401673A1 Ningalin b analogs employable for reversing multidrug resistance |
| 09/07/2001 | CA2401670A1 Human enzyme molecules |
| 09/07/2001 | CA2401667A1 Pde iv inhibiting amides, compositions and pharmaceutical use |
| 09/07/2001 | CA2401665A1 Methods for treating, screening for, and detecting cancers expressing vascular endothelial growth factor d |
| 09/07/2001 | CA2401660A1 Lipid metabolism enzymes |
| 09/07/2001 | CA2401659A1 Il-8 receptor antagonists |
| 09/07/2001 | CA2401633A1 Modulation of pleiotrophin signaling by receptor-type protein tyrosine phosphatase .beta./.zeta. |
| 09/07/2001 | CA2401621A1 Modulation of the activity of the endothelial cel surface receptor ecrtp/dep-1 in the regulation of angiogenesis |
| 09/07/2001 | CA2401613A1 Amino acids sequencing facilitating penetration of a substance of interest into cells and/or cell nuclei |
| 09/07/2001 | CA2401607A1 Methods for selectively modulating survivin apoptosis pathways |
| 09/07/2001 | CA2401533A1 Tcf responsive element |
| 09/07/2001 | CA2401453A1 G-proteins coupled receptor related polypeptides |
| 09/07/2001 | CA2401357A1 Tissue degradation inhibitor agent |
| 09/07/2001 | CA2401340A1 Compositions and methods for the treatment of inflammatory disease using topoisomerase inhibitors |
| 09/07/2001 | CA2401304A1 Combination chemotherapy |
| 09/07/2001 | CA2401175A1 Chordin-like-2 molecules and uses thereof |
| 09/07/2001 | CA2401173A1 G12l, a gene associated with the thermal response |
| 09/07/2001 | CA2401041A1 Breast cancer hormonal therapy |
| 09/07/2001 | CA2401022A1 Methods for treating fsh related conditions with gnrh antagonists |
| 09/07/2001 | CA2400649A1 3-(pyrolyllactone)-2-indolinone compounds as kinase inhibitors |
| 09/07/2001 | CA2400138A1 Pharmaceutical compositions containing 3-amino-azetidine derivatives, novel derivatives and preparation thereof |
| 09/07/2001 | CA2400116A1 Azetidine derivatives, preparation thereof and pharmaceutical compositions containing same |
| 09/07/2001 | CA2399704A1 Pyrimidine compounds |
| 09/07/2001 | CA2398685A1 2,4-di(hetero-)arylamino(-oxy)-5-substituted pyrimidines as antineoplastic agents |
| 09/07/2001 | CA2397694A1 Farnesyl protein transferase inhibitor combinations |
| 09/07/2001 | CA2397690A1 Farnesyl protein transferase inhibitor combinations with anti-tumor nucleoside derivatives |
| 09/07/2001 | CA2397657A1 Farnesyl protein transferase inhibitor combinations with platinum compounds |
| 09/07/2001 | CA2397502A1 Serine/threonine phosphatase polynucleotides, polypeptides, and antibodies |
| 09/07/2001 | CA2397475A1 Farnesyl protein transferase inhibitor combinations with vinca alkaloids |
| 09/07/2001 | CA2397448A1 Farnesyl protein transferase inhibitor combinations with further anti-cancer agents |
| 09/07/2001 | CA2397446A1 Combinations of a farnesyl protein transferase inhibitor with nitrogen mustard or nitrosourea alkylating agents |
| 09/07/2001 | CA2397425A1 Farnesyl protein transferase inhibitor combinations with taxane compounds |
| 09/07/2001 | CA2397349A1 Farnesyl protein transferase inhibitor combinations with an her2 antibody |
| 09/07/2001 | CA2397256A1 Farnesyl protein transferase inhibitor combinations with anti-tumor podophyllotoxin derivatives |
| 09/07/2001 | CA2397253A1 Farnesyl protein transferase inhibitor combinations with anti-tumor anthracycline derivatives |
| 09/07/2001 | CA2397240A1 Farnesyl protein transferase inhibitor combinations with camptothecin compounds |
| 09/07/2001 | CA2372185A1 Novel pharmaceutical or dietetic mushroom-based compositions |
| 09/07/2001 | CA2370741A1 Method for detecting and killing epithelial cancer cells |
| 09/06/2001 | US20010020042 Fluorophenyl-substituted alkenylcarboxylic acid guanidides, process for their preparation, their use as a medicament or diagnostic, and medicament containing them |
| 09/06/2001 | US20010020034 Isothiazole derivatives useful as anticancer agents |
| 09/06/2001 | US20010020021 Metalloprotease inhibitor |
| 09/06/2001 | US20010020016 Formulation |
| 09/06/2001 | US20010020013 Polymerase inhibitors |
| 09/06/2001 | US20010019715 Administering a cytotoxic T-lymphocyte and one agent capable of neutralizing or down regulating the activity of tumor secreted immunosuppressive factors |
| 09/06/2001 | DE10008159A1 Verwendung von 2-Methyl-thiazolidin-2,4-dicarbonsäure (2-MTDC) und /oder ihrer physiologisch verträglichen Salze zur Behandlung und/oder Prophylaxe von Krebserkrankungen Use of 2-methyl-thiazolidine-2,4-dicarboxylic acid (2-MTCD) and / or their physiologically tolerable salts for the treatment and / or prophylaxis of cancer |